Gadoversetamide
Chemical compound
- EU EMA: by INN
administration
- V08CA06 (WHO)
- 131069-91-5
Y
- 6435809
- DB00538
Y
- 392041
Y
- RLM74T3Z9D
- D01646
Y
- ChEMBL1200457
N
- DTXSID10156865
- Interactive image
- [Gd+3].O=C(NCCOC)CN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC(=O)NCCOC)CC([O-])=O
- InChI=1S/C20H37N5O10.Gd/c1-34-9-3-21-16(26)11-24(14-19(30)31)7-5-23(13-18(28)29)6-8-25(15-20(32)33)12-17(27)22-4-10-35-2;/h3-15H2,1-2H3,(H,21,26)(H,22,27)(H,28,29)(H,30,31)(H,32,33);/q;+3/p-3
Y
- Key:HBEAOBRDTOXWRZ-UHFFFAOYSA-K
Y
![☒](http://upload.wikimedia.org/wikipedia/commons/thumb/a/a2/X_mark.svg/7px-X_mark.svg.png)
![check](http://upload.wikimedia.org/wikipedia/en/thumb/f/fb/Yes_check.svg/7px-Yes_check.svg.png)
Gadoversetamide is a gadolinium-based MRI contrast agent, particularly for imaging of the brain, spine and liver.[1][2] It is marketed under the trade name OptiMARK.
Notes
- ^ "Gadoversetamide Drug Information". Drugs.com. 2000-03-20. Archived from the original on 2007-10-10. Retrieved 2007-03-23.
- ^ Cheng KT (10 December 2007). "Gadoversetamide: Gd-DTPA-BMEA". Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US). PMID 20641436.
- v
- t
- e
Iodinated, Water soluble |
| ||||||
---|---|---|---|---|---|---|---|
Iodinated, Water insoluble |
| ||||||
Non-iodinated |
Paramagnetic | |
---|---|
Superparamagnetic |
|
Other |
- Microspheres of human albumin
- Microparticles of galactose
- Perflenapent
- Microspheres of phospholipids
- Sulfur hexafluoride
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
![]() | This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e
![]() | This article about magnetic resonance imaging is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e